Year: 2026

Introduction Every pharma export quote comes down to more than just the product price — the Incoterm attached to it determines who pays for freight, who carries the risk in transit, and where responsibility legally shifts from seller to buyer. For pharmaceutical shipments specifically, where temperature control, insurance, and timely customs clearance carry higher stakes than most cargo categories, getting the CIF vs FOB choice right matters more than it might for general goods. This guide breaks down what each term actually means for a pharma exporter and buyer, and which one tends to fit better depending on the shipment. What Incoterms Are, Briefly Incoterms are standardised trade terms established by the International Chamber of Commerce that define the responsibilities of buyers and sellers in international trade. There are 11 terms under the current Incoterms 2020 rules, which took effect in January 2020 and remain the applicable standard, with no near-term update expected. For sea-freight pharma shipments — still the dominant mode for bulk exports to Africa — FOB and CIF are the two most commonly negotiated terms. FOB (Free on Board): What It Means Under FOB, the seller is responsible for packaging, pickup, and delivery of the goods onto a vessel at the port of shipment. Liability transfers to the buyer once the goods are on board the vessel, and the buyer is responsible for every other step of the journey from that point. In practice for a pharma exporter: You (the exporter) handle export clearance, transport to the origin port, and loading onto the vessel Once goods are loaded, the buyer takes on freight cost, insurance, and all risk for the sea journey This gives the buyer greater flexibility and control over shipping costs and schedules, since they choose the carrier and negotiate freight rates directly CIF (Cost, Insurance, and Freight): What It Means Under CIF, the seller’s responsibility for the goods extends to the port of destination, but their risk for the goods ends when the goods are loaded onto the vessel at the port of export. The seller is required to insure the goods for the portion of the journey between origin and destination, and if goods are damaged in transit, the buyer bears the loss even though the seller arranged the shipping contract. In practice for a pharma exporter: You handle export clearance, freight cost, and insurance all the way to the destination port Risk technically transfers to the buyer once goods are loaded at origin — but you remain responsible for arranging (and paying for) the insurance covering that transit risk CIF is frequently preferred by smaller or growing buyers who want simplicity and predictability, since they don’t need to arrange their own freight and insurance contracts Key Differences at a Glance FOB CIF Who pays freight Buyer Seller Who arranges insurance Buyer Seller Where cost responsibility ends for seller Port of origin (loading) Port of destination Where risk transfers Port of origin (loading) Port of origin (loading) — despite seller paying freight/insurance beyond that point Buyer’s control over carrier/routing High Low Typical preference More experienced exporters and buyers Smaller or first-time buyers wanting predictability The point most exporters find counterintuitive: under both terms, risk transfers at the same point — when goods are loaded onto the vessel. CIF doesn’t mean the seller carries risk longer; it means the seller pays for freight and insurance longer, while the buyer still bears the actual risk of loss once goods are on board. Why This Matters More for Pharma Shipments Specifically Clearance Steps Customs officers verify goods against declared documentation, examine cargo physically or via scanning, and confirm HS code classification and assessed value. Duty is then assessed based on CIF value and paid in naira through an approved bank before cargo release. Regulated goods require sign-off from the relevant agency — NAFDAC clears food and pharmaceuticals specifically — after which the NCS issues a release order for final delivery. Practical Steps for Exporters Right Now ✔ Verify your specific product’s HS code against the current prohibition list before committing to any shipment — don’t rely on pre-2026 assumptions about what’s importable ✔ Consider repositioning toward API supply for Nigerian manufacturers who still need imported raw materials to produce banned finished-product categories domestically ✔ Use the Advance Ruling mechanism for any product where classification is unclear, rather than shipping and risking rejection at port ✔ Check whether your specific product is domestically manufactured in Nigeria — specialized products without local production capacity may sit outside the ban’s practical intent, but this needs individual verification, not assumption ✔ Watch for further policy updates, since this is a recently implemented and actively debated policy shift with ongoing industry pushback Which Term Fits Which Situation FOB tends to fit better when: The buyer has an established relationship with a reliable freight forwarder in the destination market The buyer wants direct control over carrier selection and shipping schedule The exporter wants to limit its liability and paperwork to the port of origin CIF tends to fit better when: The buyer is newer to importing and prefers a simpler, more predictable landed-cost quote The exporter has established, reliable freight and insurance partners and wants to offer a more complete service The transaction benefits from the exporter maintaining visibility over the shipment through to the destination port Practical Tips for Pharma Exporters ✔ Specify insurance coverage terms explicitly in CIF contracts — don’t leave “minimum cover” ambiguous for high-value or temperature-sensitive products ✔ Confirm which party is responsible for cold-chain monitoring equipment and documentation, since neither FOB nor CIF addresses this by default ✔ Discuss Incoterm preference with African distributor partners directly rather than assuming — buyer sophistication varies significantly by market and company size ✔ Keep quotes clearly labeled with the specific Incoterm and rules version (Incoterms 2020) to avoid ambiguity in cross-border contracts Conclusion CIF vs FOB for pharmaceutical exports isn’t just a shipping-cost decision — it shapes who controls the journey, who arranges insurance, and how much documentation

Introduction Exporting medicines to Nigeria changed significantly in 2026, and any exporter working from older information is operating on an outdated picture. This guide covers what’s actually current — including a major policy shift that directly affects finished pharmaceutical exports from India — alongside the customs classification, duty calculation, and clearance process that still apply to what remains importable. What WHO-GMP Certification Actually Confirms Effective April 1, 2026, Nigeria’s Federal Ministry of Finance introduced a revised Import Prohibition List banning the importation of medicaments — pharmaceutical products — from countries outside the Economic Community of West African States (ECOWAS), as part of the 2026 Fiscal Policy Measures. Since India is not an ECOWAS member, this ban applies directly to finished-dosage exports from Indian manufacturers. The banned category covers medicaments under HS Codes 3003.10.00.00 through 3004.90.90.00, including common products such as paracetamol tablets and syrups, metronidazole, cotrimoxazole, and chloroquine. Other widely used products — multivitamin capsules, aspirin, folic acid, and ointments such as penicillin and gentamicin — are now restricted to local manufacturers, while importation of pharmaceutical waste under HS Code 3006.92.00.00 remains separately and strictly forbidden. Why this matters right now: Nigeria has historically sourced 60–65% of its medicines from abroad, especially Active Pharmaceutical Ingredients, and the policy shift is designed to cut that import dependence, conserve foreign exchange, and push local manufacturing to the forefront. Industry groups including the Pharmaceutical Society of Nigeria have raised concerns that domestic manufacturing capacity isn’t yet positioned to absorb this shift. Local manufacturers cite steep operating challenges — energy costs alone account for roughly 40% of overall manufacturing cost, with many plants running on diesel or petrol generators due to unreliable grid supply. What This Means for Indian Exporters Finished Dosage Forms Are Largely Restricted Common generic finished products — many of the categories exporters have traditionally shipped to Nigeria — now fall under the ban when sourced from non-ECOWAS countries. This affects standard tablet, syrup, and capsule exports covered by the listed HS codes. APIs Remain Importable, Under Permit NAFDAC’s own March 2026 guidelines for the importation of Active Pharmaceutical Ingredients confirm that API imports continue, requiring an import permit application detailing the applicant’s address, the API source location, the specific APIs involved, and the purpose — whether importation, distribution, sale, or manufacturing of a finished pharmaceutical product. This tracks with the underlying reality that Nigerian pharmaceutical manufacturers still heavily depend on imported APIs, since the country lacks a functional petrochemical industry capable of producing them locally. This is a significant opening for Indian exporters: rather than exporting finished paracetamol or metronicazole tablets, supplying the APIs that Nigerian manufacturers need to produce them domestically remains a viable, permitted route. Specialized and Non-Locally-Produced Medicines May Still Have a Path The ban’s stated intent is to protect domestic manufacturing of commonly produced medicines. Products Nigeria doesn’t manufacture domestically — including many oncology, specialized antiretroviral, and other niche formulations — warrant individual verification against the current prohibition list and NAFDAC guidance, since blanket assumptions in either direction are risky. ECOWAS-Sourced Goods Are Exempt The restriction applies specifically to goods originating from non-ECOWAS member states, effectively encouraging regional trade within West Africa. This doesn’t open a direct path for Indian exporters, but it’s relevant context for understanding the policy’s regional trade logic. Standard Customs Process (For What Remains Importable) HS Code Classification The ban’s stated intent is to protect domestic manufacturing of commonly produced medicines. Products Nigeria doesn’t manufacture domestically — including many oncology, specialized antiretroviral, and other niche formulations — warrant individual verification against the current prohibition list and NAFDAC guidance, since blanket assumptions in either direction are risky. Duty Calculation Import duty in Nigeria is calculated using the CIF method — Cost, Insurance, and Freight — with the applicable duty rate from the HS code multiplied by the CIF value. Additional charges include a 7% surcharge on duty, 4% FCS on FOB value, 0.5% ETLS on FOB value, and 7.5% VAT on the cumulative total. Required Documentation All imports require Form M, a Pre-Arrival Assessment Report (PAAR), commercial invoice, bill of lading or airway bill, packing list, a Combined Certificate of Value and Origin (CCVO), and proof of duty payment through the NICIS II system. Regulated goods additionally require NAFDAC permits and, where applicable, a SONCAP certificate — all lodged electronically through NICIS II. Clearance Steps Customs officers verify goods against declared documentation, examine cargo physically or via scanning, and confirm HS code classification and assessed value. Duty is then assessed based on CIF value and paid in naira through an approved bank before cargo release. Regulated goods require sign-off from the relevant agency — NAFDAC clears food and pharmaceuticals specifically — after which the NCS issues a release order for final delivery. Practical Steps for Exporters Right Now ✔ Verify your specific product’s HS code against the current prohibition list before committing to any shipment — don’t rely on pre-2026 assumptions about what’s importable ✔ Consider repositioning toward API supply for Nigerian manufacturers who still need imported raw materials to produce banned finished-product categories domestically ✔ Use the Advance Ruling mechanism for any product where classification is unclear, rather than shipping and risking rejection at port ✔ Check whether your specific product is domestically manufactured in Nigeria — specialized products without local production capacity may sit outside the ban’s practical intent, but this needs individual verification, not assumption ✔ Watch for further policy updates, since this is a recently implemented and actively debated policy shift with ongoing industry pushback Conclusion Exporting medicines to Nigeria in 2026 looks meaningfully different than it did even a year ago. The finished-dosage import ban from non-ECOWAS countries is a real constraint on the traditional generics export model, but it also opens a clearer opportunity around API supply and specialized products outside Nigeria’s current manufacturing capacity. Exporters who verify their specific product’s status rather than working off outdated assumptions — and who adapt their product mix accordingly — are better positioned than those still planning around the

Introduction Ask any pharmaceutical exporter what the single most repeated requirement is across NAFDAC, PPB Kenya, and FDA Ghana applications, and the answer is the same: WHO-GMP certification. It’s the one credential that shows up in every registration dossier, every buyer due-diligence checklist, and increasingly, every tender document across African markets. Understanding WHO-GMP certification requirements for African market entry isn’t just a compliance checkbox — it’s often the difference between a manufacturer that gets shortlisted by distributors and one that doesn’t get a second look. What WHO-GMP Certification Actually Confirms WHO Good Manufacturing Practice regulations contain requirements for the methods, facilities, and controls used in the manufacture, processing, packaging, or holding of a pharmaceutical product, meant to ensure products meet the safety, quality, and efficacy they claim to represent. It’s a facility-level and systems-level certification — covering how a product is made, not just what the finished product tests as. Because Africa lacks a single continental regulator, each country manages its own approval process through its own National Medicines Regulatory Authority, with distinct requirements, formats, and timelines — though the African Medicines Agency and regional harmonization initiatives are beginning to unify these approaches. Despite this fragmentation, every major African market accepts the CTD dossier format for registration, and WHO-GMP compliance is a consistent underlying expectation across them. How WHO-GMP Is Verified Across Key African Markets Nigeria (NAFDAC) NAFDAC’s own GMP guidelines are explicitly structured around WHO good manufacturing practice principles for pharmaceutical products, and facility compliance with these standards underpins product registration eligibility. Ghana (FDA Ghana) FDA Ghana’s guideline on GMP requirements draws directly on WHO Technical Report Series guidance on good manufacturing practices for pharmaceutical products, forming the legal and technical basis for its facility inspection process. typical plant GMP audit for first-time registration reviews the pharmaceutical quality system, GMP compliance, sanitation and hygiene, qualification and validation, complaints handling, product recall procedures, and documentation practices — with the process taking approximately three months for a first-time audit and two months for renewal. Kenya and Broader Regional Standards Regulators increasingly calibrate GMP expectations against WHO-GMP and PIC/S-aligned practices, with reliance mechanisms allowing authorities to leverage prior trusted regulatory decisions, inspection reports, or WHO Prequalification outcomes to streamline national decisions — though this reliance remains at the discretion of each national authority. What a WHO-GMP Facility Audit Typically Covers Auditors generally expect documentation covering seventeen core areas at the manufacturing site, including: Pharmaceutical Quality System Good Manufacturing Practices for Pharmaceutical Products Sanitation and Hygiene Qualification and Validation Complaints Handling Product Recall Procedures Contract Production, Analysis, and Other Outsourced Activities Self-Inspection, Quality Audits, and Supplier Approval Personnel, Training, and Personal Hygiene Premises and Equipment Materials Handling Documentation Practices Good Practices in Production Good Practices in Quality Control Deficiencies identified during inspection are classified as critical, major, or other, and are communicated to the manufacturer along with a requirement for corrective and preventive action. Why WHO-GMP Matters Beyond Just Passing Registration ✔ It’s a prerequisite embedded in every downstream approvalCOPP issuance, FSC applications, and product registration dossiers across Nigerian, Kenyan, and Ghanaian regulators all reference GMP compliance as foundational. ✔ Buyers use it as a shortlisting filter Distributorsand institutional buyers routinely screen out manufacturers who can’t produce current WHO-GMP documentation before even reviewing pricing. ✔ It supports faster registration through reliance mechanismsAs African regulators increasingly reference WHO Prequalification and prior trusted regulatory decisions, a strong existing GMP compliance record can streamline registration timelines rather than starting from zero each time. ✔ It signals credibility beyond the specific productA facility-wide certification, rather than a single-product approval, tells buyers something about consistency across an entire manufacturing operation — not just one SKU. Common Gaps That Delay or Fail GMP-Linked Approvals Expired or Missing Registration Certificates Frequent issues include expired or missing registration certificates, nonconforming labels, incomplete batch documentation, and inadequate temperature-control records. Documentation Not Aligned with the Approved Dossier Regulators expect submitted documents to align precisely with the approved dossier, alongside maintained, validated shipping evidence. Incomplete Quality System Documentation Gaps in the seventeen core documentation areas — particularly self-inspection records and supplier approval processes — are common findings during facility audits. Tips for Exporters Building Toward African Market Entry ✔ Treat WHO-GMP certification as a standing operational requirement, not a one-time project completed before your first export ✔ Keep documentation across all seventeen core audit areas current and audit-ready at all times, not assembled reactively before an inspection ✔ Maintain validated temperature-control and shipping records continuously, since these are frequently flagged gaps during review ✔ Where possible, pursue WHO Prequalification alongside national GMP compliance, since it increasingly supports faster registration through regulatory reliance mechanisms Conclusion WHO-GMP certification isn’t a single hurdle to clear before entering African markets — it’s the foundation that NAFDAC, PPB, and FDA Ghana registration processes are all built on top of, and increasingly, what buyers themselves screen for before any commercial conversation even starts. Manufacturers who treat GMP compliance as an ongoing operational standard, rather than a certificate to renew reactively, move through registration faster and win more buyer trust across every African market they enter. Salvavidas Pharma, a WHO-GMP certified pharmaceutical manufacturer based in Surat, India, maintains this standard across its API, generics, oncology, and anti-HIV product lines specifically to support smooth, compliant entry into markets like Nigeria, Kenya, and Ghana.